Severe mpox has been observed in people with advanced HIV. We describe clinical outcomes of 13 patients with advanced HIV (CD4 <200 cells/mm3), severe mpox, and multi-organ involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.